Skip to main content

What the FDA labels say about taking them together

Efavirenz and pretomanid

Pretomanid's FDA label of November 15, 2024 names efavirenz in its drug interactions section; the efavirenz label PlainMeds reads does not name pretomanid. The pretomanid label: “Strong or moderate CYP3A4 inducers such as rifampin or efavirenz: Avoid co-administration.”

Check it at the source: the efavirenz FDA label on DailyMed (effective March 31, 2024, Cipla USA Inc.); the pretomanid FDA label on DailyMed (effective November 15, 2024, Viatris Specialty LLC).

What does the efavirenz label say about pretomanid?

Efavirenz's label (effective March 31, 2024) does not name pretomanid in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Efavirenz), Cipla USA Inc., effective March 31, 2024 (SPL set 92603fa5-7a2c-4bfb-9a70-aadb4fba952c), via openFDA; the full label on DailyMed

What does the pretomanid label say about efavirenz?

Pretomanid label, drug interactions

Strong or moderate CYP3A4 inducers such as rifampin or efavirenz: Avoid co-administration.

Pretomanid label, warnings and precautions

Avoid co‑administration of strong or moderate CYP3A4 inducers, such as rifampin or efavirenz, during treatment with pretomanid.

Source: FDA drug label (Pretomanid), NDA212862 (Mylan Ireland Ltd), as published by Viatris Specialty LLC, effective November 15, 2024 (SPL set f1906fc9-cb3c-4e13-8a4a-da76100c1bf3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

5Efavirenz generic labelers
0Pretomanid generic labelers
EfavirenzPretomanid
Labeled forHIVn/a
Boxed warningNoNo
Pharmacy cost (NADAC)$1.28 per tablet 600 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?